{"id":334,"date":"2016-06-27T08:41:07","date_gmt":"2016-06-27T08:41:07","guid":{"rendered":"http:\/\/www.farmacovigilanciacanarias.org\/noticias\/?p=334"},"modified":"2016-06-27T08:41:07","modified_gmt":"2016-06-27T08:41:07","slug":"nota-informativa-muh-fv-122016","status":"publish","type":"post","link":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/2016\/06\/27\/nota-informativa-muh-fv-122016\/","title":{"rendered":"Nota Informativa MUH (FV), 12\/2016"},"content":{"rendered":"<p><a href=\"http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2016\/NI-MUH_FV_12-riociguat-Adempas.htm\">Riociguat (\u25bcAdempas): contraindicado en pacientes con hipertensi\u00f3n pulmonar asociada a neumon\u00edas intersticiales idiop\u00e1ticas (HP-NII)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Riociguat (\u25bcAdempas): contraindicado en pacientes con hipertensi\u00f3n pulmonar asociada a neumon\u00edas intersticiales idiop\u00e1ticas (HP-NII)<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-334","post","type-post","status-publish","format-standard","hentry","category-seguridad"],"_links":{"self":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/comments?post=334"}],"version-history":[{"count":1,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/334\/revisions"}],"predecessor-version":[{"id":335,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/334\/revisions\/335"}],"wp:attachment":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/media?parent=334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/categories?post=334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/tags?post=334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}